[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
February 2018

Personalized Medicine and the Contradictions and Limits of First-Generation Deescalation Trials in Patients With Human Papillomavirus–Positive Oropharyngeal Cancer

Author Affiliations
  • 1Radiotherapy 2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • 2Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • 3University of Milan, Italy
JAMA Otolaryngol Head Neck Surg. 2018;144(2):99-100. doi:10.1001/jamaoto.2017.2308

In recent years, the term “personalized medicine,” which indicates a treatment tailored for each individual patient, has been widely replaced by the term “precision medicine.” This latter, in a more accurate and broader way, associates patient’s care with genetic, environmental, clinical, and lifestyle factors. In the oncological community, precision medicine refers to genomics-driven cancer medicine.1